SAFETY DATA SHEET

Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation

SECTION 1. IDENTIFICATION

Product name: Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation

Other means of identification: No data available

Manufacturer or supplier’s details

Company name of supplier: Organon & Co.
Address: 30 Hudson Street, 33nd floor
                    Jersey City, New Jersey, U.S.A 07302
Telephone: 551-430-6000
Emergency telephone: 215-631-6999
E-mail address: EHSSTEWARD@organon.com

Recommended use of the chemical and restrictions on use

Recommended use: Pharmaceutical

Restrictions on use: Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the Hazardous Products Regulations

Combustible dust: Category 1
Eye irritation: Category 2A
Reproductive toxicity: Category 1A
Specific target organ toxicity - repeated exposure: Category 1 (Kidney, Parathyroid gland)

GHS label elements

Hazard pictograms:

Signal Word: Danger

Hazard Statements:
May form combustible dust concentrations in air.
H319 Causes serious eye irritation.
H360D May damage the unborn child.
H372 Causes damage to organs (Kidney, Parathyroid gland) through prolonged or repeated exposure.

Precautionary Statements:
Prevention:
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
SAFETY DATA SHEET

Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation

P260 Do not breathe dust.
P264 Wash skin thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P280 Wear protective gloves, protective clothing, eye protection and face protection.

Response:
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P308 + P313 IF exposed or concerned: Get medical attention.
P337 + P313 If eye irritation persists: Get medical attention.

Storage:
P405 Store locked up.

Disposal:
P501 Dispose of contents and container to an approved waste disposal plant.

Other hazards
Contact with dust can cause mechanical irritation or drying of the skin.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>Common Name/Synonym</th>
<th>CAS-No.</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cellulose</td>
<td>No data available</td>
<td>9004-34-6</td>
<td>&gt;= 30 - &lt; 60 *</td>
</tr>
<tr>
<td>Starch</td>
<td>Sago starch</td>
<td>9005-25-8</td>
<td>&gt;= 30 - &lt; 60 *</td>
</tr>
<tr>
<td>Olmesartan</td>
<td>No data available</td>
<td>144689-63-4</td>
<td>&gt;= 10 - &lt; 30 *</td>
</tr>
<tr>
<td>Hydrochlorothiazide</td>
<td>No data available</td>
<td>58-93-5</td>
<td>&gt;= 5 - &lt; 10 *</td>
</tr>
<tr>
<td>Amlodipine Besylate</td>
<td>No data available</td>
<td>652969-01-2</td>
<td>&gt;= 1 - &lt; 5 *</td>
</tr>
</tbody>
</table>

* Actual concentration or concentration range is withheld as a trade secret

SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air. Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.

In case of eye contact: In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. If easy to do, remove contact lens, if worn. Get medical attention.

If swallowed: If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed: Causes serious eye irritation. May damage the unborn child. Causes damage to organs through prolonged or repeated exposure. Contact with dust can cause mechanical irritation or drying of the skin.

Protection of first-aiders: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician: Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

<table>
<thead>
<tr>
<th>Suitable extinguishing media</th>
<th>Water spray</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Alcohol-resistant foam</td>
</tr>
<tr>
<td></td>
<td>Carbon dioxide (CO2)</td>
</tr>
<tr>
<td></td>
<td>Dry chemical</td>
</tr>
</tbody>
</table>

| Unsuitable extinguishing media | High volume water jet |

| Specific hazards during fire fighting | Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Do not use a solid water stream as it may scatter and spread fire. Exposure to combustion products may be a hazard to health. |

<table>
<thead>
<tr>
<th>Hazardous combustion products</th>
<th>Carbon oxides</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Nitrogen oxides (NOx)</td>
</tr>
<tr>
<td></td>
<td>Chlorine compounds</td>
</tr>
<tr>
<td></td>
<td>Sulfur oxides</td>
</tr>
</tbody>
</table>

| Specific extinguishing methods | Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area. |

| Special protective equipment for fire-fighters | In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment. |

SECTION 6. ACCIDENTAL RELEASE MEASURES

| Personal precautions, protection | Use personal protective equipment. |
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

Sweep up or vacuum up spillage and collect in suitable container for disposal.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures: Static electricity may accumulate and ignite suspended dust causing an explosion.
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation: If sufficient ventilation is unavailable, use with local exhaust ventilation.

Advice on safe handling:
Do not get on skin or clothing.
Do not breathe dust.
Do not swallow.
Do not get in eyes.
Wash skin thoroughly after handling.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment.
Keep container tightly closed.
Minimize dust generation and accumulation.
Keep container closed when not in use.
Keep away from heat and sources of ignition.
Do not eat, drink or smoke when using this product.
Take care to prevent spills, waste and minimize release to the environment.

Conditions for safe storage:
Keep in properly labeled containers.
Store locked up.
Keep tightly closed.
Store in accordance with the particular national regulations.

Materials to avoid:
Do not store with the following product types:
Strong oxidizing agents
Organic peroxides
SAFETY DATA SHEET

Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cellulose</td>
<td>9004-34-6</td>
<td>TWA</td>
<td>10 mg/m³</td>
<td>CA AB OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (Total dust)</td>
<td>10 mg/m³</td>
<td>CA BC OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (respirable dust fraction)</td>
<td>3 mg/m³</td>
<td>CA BC OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWAEV (total dust)</td>
<td>10 mg/m³</td>
<td>CA QC OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA</td>
<td>10 mg/m³</td>
<td>ACGIH</td>
</tr>
<tr>
<td>Starch</td>
<td>9005-25-8</td>
<td>TWA</td>
<td>10 mg/m³</td>
<td>CA AB OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWAEV (total dust)</td>
<td>10 mg/m³</td>
<td>CA QC OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (Total dust)</td>
<td>10 mg/m³</td>
<td>CA BC OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (respirable dust fraction)</td>
<td>3 mg/m³</td>
<td>CA BC OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA</td>
<td>10 mg/m³</td>
<td>ACGIH</td>
</tr>
<tr>
<td>Olmesartan</td>
<td>144689-63-4</td>
<td>TWA</td>
<td>30 µg/m³ (OEB 3) Internal</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wipe limit</td>
<td>300 µg/100 cm² Internal</td>
<td></td>
</tr>
<tr>
<td>Hydrochlorothiazide</td>
<td>58-93-5</td>
<td>TWA</td>
<td>100 µg/m³ (OEB 2) Internal</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wipe limit</td>
<td>100 µg/100 cm² Internal</td>
<td></td>
</tr>
<tr>
<td>Amlodipine Besylate</td>
<td>652969-01-2</td>
<td>TWA</td>
<td>20 µg/m³ (OEB 3) Internal</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wipe limit</td>
<td>100 µg/100 cm² Internal</td>
<td></td>
</tr>
</tbody>
</table>

Engineering measures:
Use feasible engineering controls to minimize exposure to compound.
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Personal protective equipment

Respiratory protection:
If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type: Particulates type

Hand protection Material:
Chemical-resistant gloves

Eye protection:
Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection

Hygiene measures:

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Work uniform or laboratory coat.

If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.

When using do not eat, drink or smoke.

Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

### SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

**Appearance**: tablet

**Color**: No data available

**Odor**: No data available

**Odor Threshold**: No data available

**pH**: No data available

**Melting point/freezing point**: No data available

**Initial boiling point and boiling range**: No data available

**Flash point**: No data available

**Evaporation rate**: Not applicable

**Flammability (solid, gas)**: No data available

**Flammability (liquids)**: No data available

**Upper explosion limit / Upper flammability limit**: No data available

**Lower explosion limit / Lower flammability limit**: No data available

**Vapor pressure**: Not applicable

**Relative vapor density**: Not applicable

**Relative density**: No data available

**Density**: No data available
Solubility(ies)
Water solubility : No data available
Partition coefficient: n-octanol/water : Not applicable
Autoignition temperature : No data available
Decomposition temperature : No data available
Viscosity
Viscosity, kinematic : Not applicable
Explosive properties : Not explosive
Oxidizing properties : The substance or mixture is not classified as oxidizing.
Molecular weight : No data available
Particle size : No data available

SECTION 10. STABILITY AND REACTIVITY
Reactivity : Not classified as a reactivity hazard.
Chemical stability : Stable under normal conditions.
Possibility of hazardous reactions
Dust can form an explosive mixture in air.
Can react with strong oxidizing agents.
Conditions to avoid
Avoid dust formation.
Incompatible materials
Oxidizing agents
Hazardous decomposition products
No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION
Information on likely routes of exposure
Inhalation
Skin contact
Ingestion
Eye contact
Acute toxicity
Not classified based on available information.
Product:
Acute oral toxicity : Acute toxicity estimate: > 5,000 mg/kg
Method: Calculation method
Components:
Cellulose:
Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg
Acute inhalation toxicity: LC50 (Rat): > 5.8 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist

Acute dermal toxicity: LD50 (Rabbit): > 2,000 mg/kg

Starch:
Acute oral toxicity: LD50 (Rat): > 5,000 mg/kg
Acute dermal toxicity: LD50 (Rabbit): > 2,000 mg/kg

Olmesartan:
Acute oral toxicity: LD50 (Rat): > 2,000 mg/kg
    LD50 (Mouse): > 2,000 mg/kg
    LD50 (Dog): > 1,500 mg/kg
Acute inhalation toxicity: Remarks: No data available
Acute dermal toxicity: Remarks: No data available

Hydrochlorothiazide:
Acute oral toxicity: LD50 (Rat): > 2,750 mg/kg
    LD50 (Mouse): > 2,830 mg/kg
Acute toxicity (other routes of administration):
    LD50 (Rat): 990 mg/kg
    Application Route: Intravenous
    LD50 (Mouse): 590 mg/kg
    Application Route: Intravenous

Amlodipine Besylate:
Acute oral toxicity: LD50 (Rat): 393 mg/kg

Skin corrosion/irritation
Not classified based on available information.

Components:

Olmesartan:
Remarks: No data available

Hydrochlorothiazide:
Species: Rabbit
Result: No skin irritation
### Serious eye damage/eye irritation
Causes serious eye irritation.

**Components:**

<table>
<thead>
<tr>
<th>Component</th>
<th>Species</th>
<th>Result</th>
<th>Method</th>
</tr>
</thead>
<tbody>
<tr>
<td>Starch</td>
<td>Rabbit</td>
<td>No eye irritation</td>
<td></td>
</tr>
<tr>
<td>Olmesartan</td>
<td>Rabbit</td>
<td>Moderate eye irritation</td>
<td>Draize Test</td>
</tr>
<tr>
<td>Hydrochlorothiazide</td>
<td>Rabbit</td>
<td>Mild eye irritation</td>
<td></td>
</tr>
<tr>
<td>Amlodipine Besylate</td>
<td>Rabbit</td>
<td>Severe irritation</td>
<td></td>
</tr>
</tbody>
</table>

### Respiratory or skin sensitization

**Skin sensitization**
Not classified based on available information.

**Respiratory sensitization**
Not classified based on available information.

**Components:**

<table>
<thead>
<tr>
<th>Component</th>
<th>Species</th>
<th>Result</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Starch</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Olmesartan</td>
<td></td>
<td></td>
<td>No data available</td>
</tr>
</tbody>
</table>

### Germ cell mutagenicity
Not classified based on available information.

**Components:**

| Component | Genotoxicity in vitro | Test Type: Bacterial reverse mutation assay (AMES) Result: negative |
Genotoxicity in vivo:
- Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
  Species: Mouse
  Application Route: Ingestion
  Result: negative

Starch:
- Test Type: Bacterial reverse mutation assay (AMES)
  Result: negative

Olmesartan:
- Genotoxicity in vitro:
  - Test Type: Bacterial reverse mutation assay (AMES)
    Result: negative
  - Test Type: Mutagenicity (in vitro mammalian cytogenetic test)
    Result: negative
  - Test Type: Chromosome aberration test in vitro
    Test system: Chinese hamster lung cells
    Result: positive
  - Test Type: Mouse Lymphoma
    Result: negative

- Genotoxicity in vivo:
  - Test Type: Micronucleus test
    Species: Mouse
    Cell type: Bone marrow
    Application Route: Oral
    Result: negative

Germ cell mutagenicity - Assessment:
Weight of evidence does not support classification as a germ cell mutagen.

Hydrochlorothiazide:
- Genotoxicity in vitro:
  - Test Type: Bacterial reverse mutation assay (AMES)
    Result: negative
  - Test Type: Chromosomal aberration
    Test system: Chinese hamster ovary cells
    Result: negative
  - Test Type: sister chromatid exchange assay
    Test system: Chinese hamster ovary cells
    Result: positive
  - Test Type: in vitro test
    Test system: mouse lymphoma cells
    Result: positive
Genotoxicity in vivo:
Test Type: Chromosomal aberration
Species: Chinese hamster
Cell type: Bone marrow
Result: negative

Test Type: in vivo assay
Species: Mouse
Cell type: Bone marrow
Result: negative

Germ cell mutagenicity - Assessment:
Weight of evidence does not support classification as a germ cell mutagen.

Amlodipine Besylate:
Genotoxicity in vitro:
Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: Chromosome aberration test in vitro
Result: negative

Carcinogenicity:
Not classified based on available information.

Components:

Cellulose:
Species: Rat
Application Route: Ingestion
Exposure time: 72 weeks
Result: negative

Olmesartan:
Species: Rat
Application Route: Oral
Exposure time: 2 Years
Result: negative

Species: Mouse
Application Route: Oral
Exposure time: 6 Months
Result: negative

Hydrochlorothiazide:
Species: Mouse, female
Application Route: Oral
Exposure time: 2 Years
Result: negative

Species: Mouse, male
Application Route: Oral
Exposure time: 2 Years  
Result: equivocal

Species: Rat, male and female  
Application Route: Oral  
Exposure time: 2 Years  
Result: negative

**Amlodipine Besylate:**

Species: Mouse  
Application Route: Oral  
Exposure time: 2 Years  
Result: negative

Species: Rat  
Application Route: Oral  
Exposure time: 2 Years  
Result: negative

**Reproductive toxicity**
May damage the unborn child.

**Components:**

**Cellulose:**

Effects on fertility: Test Type: One-generation reproduction toxicity study  
Species: Rat  
Application Route: Ingestion  
Result: negative

Effects on fetal development: Test Type: Fertility/early embryonic development  
Species: Rat  
Application Route: Ingestion  
Result: negative

**Olmesartan:**

Effects on fertility: Test Type: Fertility  
Species: Rat  
Application Route: Oral  
Fertility: NOAEL: 1,000 mg/kg body weight  
Result: No effects on fertility.

Effects on fetal development: Test Type: Development  
Species: Rat  
Application Route: Oral  
Dose: 1000 milligram per kilogram  
Result: No teratogenic effects.

Test Type: Development  
Species: Rabbit  
Application Route: Oral  
Dose: 1 milligram per kilogram
Result: No teratogenic effects.

Test Type: Development
Species: Rat
Application Route: Oral
Developmental Toxicity: LOAEL: >= 1.6 mg/kg body weight
Symptoms: Malformations were observed., Reduced body weight
Result: Effects on postnatal development.

Reproductive toxicity - Assessment: Positive evidence of adverse effects on development from human epidemiological studies.

**Hydrochlorothiazide:**

**Effects on fertility:**
- Test Type: Fertility
- Species: Rat, male and female
- Application Route: oral (feed)
- Fertility: NOAEL: 4 mg/kg body weight
- Result: Effects on fertility.

**Effects on fetal development:**
- Test Type: Development
- Species: Mouse, male and female
- Application Route: oral (feed)
- Fertility: NOAEL: 100 mg/kg body weight
- Result: Effects on fertility.

**Amlodipine Besylate:**

**Effects on fertility:**
- Test Type: Fertility/early embryonic development
- Species: Rat
- Application Route: Ingestion
- Fertility: NOAEL: 10 mg/kg body weight
- Result: No effects on fertility.

**Effects on fetal development:**
- Test Type: Fertility/early embryonic development
- Species: Rabbit
- Application Route: Ingestion
- Fertility: NOAEL: 25 mg/kg body weight
- Result: No effects on fertility.
Species: Rat  
Application Route: Ingestion  
Developmental Toxicity: LOAEL: 10 mg/kg body weight  
Result: Effects on fetal development.

Test Type: Embryo-fetal development  
Species: Rabbit  
Application Route: Ingestion  
Developmental Toxicity: NOAEL: 10 mg/kg body weight  
Result: No effects on fetal development.

Test Type: Embryo-fetal development  
Species: Mouse  
Application Route: Ingestion  
Developmental Toxicity: LOAEL: 1.6 mg/kg body weight  
Result: Effects on fetal development.  
Remarks: Maternal toxicity observed.

STOT-single exposure  
Not classified based on available information.

STOT-repeated exposure  
Causes damage to organs (Kidney, Parathyroid gland) through prolonged or repeated exposure.

Components:

Hydrochlorothiazide:
Target Organs : Kidney, Parathyroid gland  
Assessment : Causes damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

Cellulose:
Species : Rat  
NOAEL : >= 9,000 mg/kg  
Application Route : Ingestion  
Exposure time : 90 Days

Starch:
Species : Rat  
NOAEL : >= 2,000 mg/kg  
Application Route : Skin contact  
Exposure time : 28 Days  
Method : OECD Test Guideline 410

Olmesartan:
Species : Rat  
NOAEL : 2,000 mg/kg  
Application Route : Oral
SAFETY DATA SHEET

Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation

Exposure time: 24 Months
Remarks: No significant adverse effects were reported

Hydrochlorothiazide:

Species: Rat, male and female
LOAEL: 10 mg/kg
Application Route: Oral
Exposure time: 2 y
Target Organs: Kidney, Parathyroid gland

Species: Mouse, male and female
NOAEL: 300 - 550 mg/kg
Application Route: Oral
Exposure time: 2 y
Remarks: No significant adverse effects were reported

Species: Dog
Application Route: Oral
Exposure time: 9 Months
Target Organs: Parathyroid gland

Amlodipine Besylate:

Species: Rat
NOAEL: 15 mg/kg
Application Route: Oral
Exposure time: 90 d
Remarks: No significant adverse effects were reported

Aspiration toxicity
Not classified based on available information.

Components:

Hydrochlorothiazide:
No aspiration toxicity classification

Experience with human exposure

Components:

Olmesartan:

Eye contact: Symptoms: Eye irritation
Ingestion: Symptoms: hypotension
Remarks: May cause harm to the unborn child.
Based on Human Evidence

Hydrochlorothiazide:

Eye contact: Symptoms: Eye irritation
Ingestion: Symptoms: Dizziness, Headache, Fatigue, Nausea, Abdominal pain, hypotension, dry mouth, electrolyte imbalance, eye pain
Amlodipine Besylate:

Eye contact: Symptoms: Severe irritation
Ingestion: Symptoms: Nausea, Abdominal pain, Fatigue, Headache, Edema, Palpitation

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Cellulose:
Toxicity to fish: LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l
Exposure time: 48 h
Remarks: Based on data from similar materials

Hydrochlorothiazide:
Toxicity to fish: LC50 (Pimephales promelas (fathead minnow)): > 500 mg/l
Exposure time: 96 h
Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): > 500 mg/l
Exposure time: 48 h

Amlodipine Besylate:
Toxicity to fish: LC50 (Pimephales promelas (fathead minnow)): 2.7 mg/l
Exposure time: 96 h
Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): 3.2 mg/l
Exposure time: 48 h
Toxicity to algae/aquatic plants: IC50 (Pseudokirchneriella subcapitata (green algae)): 5.6 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

Persistence and degradability

Components:

Cellulose:
Biodegradability: Result: Readily biodegradable.

Hydrochlorothiazide:
Stability in water: Hydrolysis: 46.2 % (96 h)

Bioaccumulative potential

Components:

Amlodipine Besylate:
Partition coefficient: n- log Pow: 3
SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods
Waste from residues : Dispose of in accordance with local regulations.
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations
UNRTDG
Not regulated as a dangerous good
IATA-DGR
Not regulated as a dangerous good
IMDG-Code
Not regulated as a dangerous good
Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not applicable for product as supplied.

Domestic regulation
TDG
Not regulated as a dangerous good

SECTION 15. REGULATORY INFORMATION

The ingredients of this product are reported in the following inventories:
AICS : not determined
DSL : not determined
IECSC : not determined

SECTION 16. OTHER INFORMATION

Full text of other abbreviations
ACGIH : USA. ACGIH Threshold Limit Values (TLV)
SAFETY DATA SHEET

Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation

Version 2.0
Revision Date: 04/09/2021
SDS Number: 4944863-00004
Date of last issue: 10/10/2020
Date of first issue: 09/30/2019

CA BC OEL : Canada. British Columbia OEL
CA QC OEL : Québec. Regulation respecting occupational health and safety, Schedule 1, Part 1: Permissible exposure values for airborne contaminants
ACGIH / TWA : 8-hour, time-weighted average
CA AB OEL / TWA : 8-hour Occupational exposure limit
CA BC OEL / TWA : 8-hour time weighted average
CA QC OEL / TWA/EV : Time-weighted average exposure value

Sources of key data used to compile the Material Safety Data Sheet:

Revision Date: 04/09/2021
Date format: mm/dd/yyyy

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and...
shall not be considered a warranty or quality specification of any type. The information provided
relates only to the specific material identified at the top of this SDS and may not be valid when the
SDS material is used in combination with any other materials or in any process, unless specified
in the text. Material users should review the information and recommendations in the specific
context of their intended manner of handling, use, processing and storage, including an
assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

CA / Z8